Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.56), $0.25 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $34 million versus the consensus estimate of $37.86 million.

GUIDANCE:

2019 Financial Guidance

For the full-year 2019 the Company anticipates total Galafold revenue of $160 million to $180 million. Growth in 2019 is expected to be driven by continued growth in EU markets, further geographic expansion, and successful adoption in the first full year of launch in the U.S. and Japan. Consistent with Galafold adoption trends and ordering patterns seen in previous years, Amicus expects higher revenue growth in the second and fourth quarters of 2019.

Cash, cash equivalents, and marketable securities totaled $438.3 million at March 31, 2019. The Company expects to end 2019 with approximately $300 million in cash on hand. The current cash position is anticipated to fund ongoing operations into at least mid-2021.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.